Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

NCT07706205 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

ABO Blood Type Incompatible Kidney Transplantation

Interventions

DRUG: Blinatumomab Treatment
DRUG: Teclistamab treat

Sponsor

West China Hospital